Clinical Trial

A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-06; most recent amendment 2026-02-09.
Status change: Not Yet Recruiting → Recruiting 2025-10-30
Trial Details
NCT Number NCT07214870
Lead Sponsor Novo Nordisk A/S
Conditions Fatty Liver Disease
Enrollment 60 participants
Start Date 2025-10-08
Primary Completion 2027-05-14 (estimated)
Study Completion 2027-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-02-11